Genuit Dividends - GEN

Genuit Dividends - GEN

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
Monthly Subscription
for only
UK/US Silver
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type
Genuit Group Plc GEN London Ordinary Share
  Price Change Price Change % Stock Price Last Trade
-3.00 -0.78% 379.50 16:35:14
Open Price Low Price High Price Close Price Previous Close
375.50 370.00 383.50 379.50 382.50
more quote information »
Industry Sector

Genuit GEN Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount

Top Dividend Posts

km18: ...from last year... Company overview: Genuit Group is actually the new name of Polypipe Group plc. They provide sustainable solutions for water, climate and ventilation management. Sustainability is at the core of the firm’s strategy, driven by constant innovations. Genuit benefits from the active plans of governments across the globe to achieve net zero strategies and promote ESG activities and foresees geographic reach to be a major driver of growth for the group in the long term. Blended approach for growth, with several acquisitions and continuous Capex seems to be working for the company in the long run, as both revenues and EPS have been growing steadily over the past 6 years, with the sole exception the catharsis of 2020. Fundamentally the company is also supported by a solid history of debt retirement and cash generation. the half-year report sounds very promising. The group revenue was 32.5% above the 2019 figure (yes, that is a 3rd above the covid free year), driven by a significant raise in residential business at £183.8m (64% growth yoy lfl basis). The sole red flag on the report comes in the face of pressured margins, coming from the rising input costs. This has been balanced very nicely by 8% increase in prices for final customers, which proves the company’s brand recognition.  The labour supply issues several sectors are experiencing seems to be fading at Genuit, but we suggest keeping your eyes open for September for further guidance on the direction of the “pingdemic”. Genuit’s exposure to pen air projects is what supported the performance during the lockdowns, but the group saw drop in the commercial side of the sector. So, overall growth there is mediocre at 8.3%. Analyst consensus is expecting 9% increase in profit, built on the residentials and the acquisitions which are performing quite well. The board is expecting “underlying operating profit for FY to be ahead of expectations”....from WealthOracleAM
philanderer: xd thursday morning for the 4p dividend.
philanderer: xd tomorrow morning for the 4.8p dividend
rambutan2: yes, the sphere idea crossed my mind. i trawled through the 05 report and accounts earlier today, in part to remind myself why/whether i should still be holding. i decided to hang on in, although as always, was still not convinced that the gen model will ever be really profitable. i think it quite possible that the interims will show a loss. yes, i was struck at how little/no specific info about sgai in the annual report. just in the notes, that it a 63% subsid and that its y/e is 31 march ie different to gen.
rambutan2: interims were 30 august last year. certainly been a keen seller around over recent months - low point being a 100k sale at 8.5p on 29 aug. i think the mms deserve a bonus point for that one! elgordo, perhaps the ace in the pack is going to turn out to be the chinese venture? whatever, the current mkt cap certainly offers good upside if gen do strike some gold. and so it should, as there's lots of catching up to do - gen floated in dec 2000 at 210p!
humpja: To double the price of gen would need the 10% of sphere they hold to be rerated to £25m (assuming no dilution in the float). So sphere as a whole needs to be worth at least £250m (10x25) - which seems steep for a company with no sales. Maybe in a few years, but that's still a lot of sensors to shift. Look at CMR - great prospects but because gen has such small holding it isn't likely to set the shareprice on fire.
adejuk: sphere will come to aim in or around sept this year. distribution aggrements should be in place and it is set to take blood analysis to a new level - it may well revolutionise hospital practice adn everyone will want this machine. imho gen could double on just that one float.
games: anyone know if gen still has a stake in British Titanium, as i see they are claiming $400m from Qinetiq. Bit optimistic, but might raise their profile a bit.
kdwilson: I guess that the key impact of this near-term will be to raise GEN's profile. CRM will be seeing lots of institutions who will then also look at GEN. This will lead to interest in other spin offs etc. Still think 20p by March next year possible.
kdwilson: see page 22 of FT - The new non exec Chairman is also subscribing for £1m - that's a major endorsment of CRM. Gen could have something big on its hands...assuming CRM is as good as it looks, the market cap could easily be well north of £60m within 12 months. This on its own means Gen should be worth over 18p...before its other spin offs come to market! Silly price below 15p in my view!
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220703 06:40:24